This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Endo International (ENDP) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 271.43% and 13.72%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View
by Zacks Equity Research
Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year. Shares fall in after-hours trading.
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Ups Sales Guidance
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.
What's in Store for Turtle Beach (HEAR) This Earnings Season?
by Zacks Equity Research
Turtle Beach's (HEAR) third-quarter 2020 performance is likely to have benefited from accretive product launches and strong demand for its gaming products stemming from the COVID-19 situation.
Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.
What's in the Cards for Maxar (MAXR) This Earnings Season?
by Zacks Equity Research
Owing to the COVID-19 turmoil, Maxar's (MAXR) third-quarter earnings are likely to have been hurt by reduced commercial programs and supply chain woes.
Endo International (ENDP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Endo (ENDP) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M
by Zacks Equity Research
Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.
Avenue Therapeutics' Pain Drug Gets Complete Response Letter
by Zacks Equity Research
Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.
Implied Volatility Surging for Endo (ENDP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.
Endo Up on COVID-19 Vaccine Manufacturing Deal with Novavax
by Zacks Equity Research
Endo (ENDP) and Novavax enter a manufacturing agreement for the latter's COVID-19 vaccine candidate, NVX-CoV2373.
Endo (ENDP) Surges: Stock Moves 8.4% Higher
by Zacks Equity Research
Endo (ENDP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
BioMarin Initiates Gene Therapy Study for Phenylketonuria
by Zacks Equity Research
BioMarin (BMRN), a leader in the phenylketonuria segment, initiates development of its first gene therapy for treating the rare genetic enzyme deficiency disorder.
Endo (ENDP) Down 19.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Endo (ENDP) Q2 Earnings & Sales Beat as Coronavirus Impacts Ease
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the second quarter as COVID-19-related restrictions ease out.
Endo International (ENDP) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 85.71% and 7.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Endo International (ENDP) Q2 Earnings Expected to Decline
by Zacks Equity Research
Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endo (ENDP) Obtains FDA Approval for Cellulite Treatment
by Zacks Equity Research
Endo (ENDP) gains FDA approval for Qwo (collagenase clostridium histolyticum-aaes) for the treatment of cellulite.
Heron's Pain Management Drug Gets Complete Response Letter
by Zacks Equity Research
Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.
Endo (ENDP) Up 1.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the first quarter and lowers guidance due to the coronavirus pandemic.
BioDelivery (BDSI) Beats on Q1 Earnings, Withdraws Guidance
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues. Stock up.
Endo (ENDP) Q1 Earnings Beat on Coronavirus-Led Stockpiling
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic
Endo International (ENDP) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 75.93% and 14.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?